Molecular diagnostics company Exact Sciences and Pfizer have signed a multi-year agreement to co-market the Cologuard test for diagnosing colorectal cancer in the US.
To take place from Q4 2018 to 2021, the agreement will see Pfizer work with Exact Sciences’ sales representatives to bring the Cologuard test to physicians and health systems.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Cologuard is one of the only US Food and Drug Administration (FDA) approved and non-invasive stool DNA screening diagnostics for cancer.
By promoting the test, Exact Sciences and Pfizer intend to boost colorectal cancer screening rates.
Exact Sciences chairman and CEO Kevin Conroy said: “Pfizer is joining Exact Sciences’ mission of eradicating colorectal cancer by helping detect the disease at its earliest, most treatable stages.
“Together we can help reduce the prevalence of colorectal cancer by combining the power of Cologuard and the talented Exact Sciences team with Pfizer’s experience, relationships and resources.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company’s sales force, the science of Cologuard and a direct-to-consumer marketing campaign will be combined with Pfizer’s health systems network and marketing expertise.
Pfizer’s internal medicine North America regional president Nick Lagunowich said: “By joining forces with Exact Sciences to bring this non-invasive colorectal cancer screening option to more providers and their patients, we hope to substantially increase the early detection of colorectal cancer.”
Exact Sciences will continue to carry out all manufacturing and laboratory operations of the test. Pfizer will evenly share gross profits and marketing costs above an agreed baseline.
